Table 1.
Systematic review results and patient-level data available for meta-analysis.
Study | Country | Year | Enrollment window* |
Spot frequency** |
PPV | Number of patients+ |
---|---|---|---|---|---|---|
Demchuk et al.17 | Multicenter++ | 2012 | < 6 hours | 29% | 61% | 386 |
Wada et al.24 | Canada | 2007 | < 3 hours | 33% | 77% | 126 |
Goldstein et al.23 | USA | 2007 | None | 56% | 24% | 414 |
Li et al.19 | China | 2011 | < 6 hours | 22% | 79% | 139 |
Murai et al.32 | Japan | 1999 | < 12 hours | 21% | 60% | 24 |
Kim et al.22 | USA | 2008 | None | 18% | NR | 56 |
Sorimachi et al.16 | Japan | 2013 | < 24 hours | 21% | NR | 141 |
Rizos et al.14 | Germany | 2013 | < 6 hours | 27% | 59% | 57 |
Becker et al.33 | USA | 1999 | None | 46% | NR | NA |
Park et al.21 | Korea | 2010 | < 24 hours | 17% | NR | NA |
Wang et al.18 | China | 2011 | < 3 hours | 24% | 83% | NA |
Hallevi et al.20 | USA | 2010 | < 4 hours | 41% | 100% | NA |
Enrollment window refers to inclusion time windows of published studies.
Spot prevalence as reported in the initial publications.
As some studies continued enrollment following publication, number of patients refers to the final number available for pooled analysis.
Participating centers were in Canada, Spain, Germany, USA, Poland and India.
PPV = positive predictive value; NR = not reported in primary publication; NA = patient-level data not available